A Phase 3 interventional study of IBI362 and Placebo in Obesity, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-27.
Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing mazdutide in Obesity — 11 open to participants now, 14 under way, 4 of them phase 3. mazdutide · Obesity.
Among the 22 studies testing mazdutide in Obesity, this one is the 4th largest by enrollment, is one of 3 that started in 2023, is one of 6 in phase 3, reaches primary completion later than 0 of the 13 other live ones, and was the 8th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →11 of the 22 studies testing mazdutide in Obesity are open now, in 3 countries. Recruiting first, the newest first:
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
Shanghai Zhongshan Hospital · Sites in China
Ages 18+
China-Japan Friendship Hospital · Sites in China
Ages 18–60
Innovent Biologics (Suzhou) Co. Ltd. · Sites in China
Ages 18+
Innovent Biologics (Suzhou) Co. Ltd. · Sites in China
Ages 12–18
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, mazdutide is the treatment under test here. Read study by study →
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 7 · Phase 3 6 · Phase 4 2
First in 2020; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 462 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 187 across the 22 interventional studies. Of the 8 that completed or were terminated, 1 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 22 have an industry lead sponsor. The 8 most frequent:
This study is registered under Innovent Biologics (Suzhou) Co. Ltd., one of the names counted as Innovent Biologics, Inc.. Under that name alone:
Innovent Biologics (Suzhou) Co. Ltd. is the lead sponsor of 199 studies on the registry; 46 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
16 studies in Obesity by Innovent Biologics, Inc.: 5 open now, 9 under way, 4 of them phase 3. Of 7 finished, 0 (0%) have results posted.
Among the 16 studies in Obesity by Innovent Biologics, Inc., this one is the 2nd largest by enrollment, is the only one that started in 2023, is one of 6 in phase 3, and was the 5th registered.
Innovent Biologics, Inc.’s Obesity studies by the year they started, since 2020.
3 of the studies testing mazdutide in Obesity that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06931028Phase 3Innovent Biologics (Suzhou) Co. Ltd.A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2 | 2027-05-07 |
| NCT07255209Phase 3Innovent Biologics (Suzhou) Co. Ltd.A Study of IBI362 in Chinese Adolescents With Obesity or Overweight | 2027-10-31 |
| NCT06143956Eli Lilly and CompanyA Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 22 studies testing mazdutide in Obesity, from their registry updates:
Among Innovent Biologics, Inc.’s 16 in Obesity:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical study evaluating the efficacy and safety of IBI362 9 mg in obese subjects. Subjects will be randomly assigned to IBI362 9 mg and placebo groups. All study treatment will be administered once-weekly and subcutaneously. The entire trial cycle includes a 2-week screening period, a 60-week double-blind treatment period, and a 12-week drug withdrawal follow-up period after the end of treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For subjects with T2D at screening:
Exclusion Criteria:
For subjects without T2D at screening:
For subjects with T2D at screening:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo
Drug: IBI362
Once-weekly injections of gradually increased doses of IBI362
Once-weekly injections of volume-matched placebo
Percent Change from Baseline in Body Weight
Time frame: Week 60
Proportion of Participants who Achieve ≥5% Body Weight Reduction
Time frame: Week 60
Proportion of Participants who Achieve ≥10% Body Weight Reduction
Time frame: Week 60
Proportion of Participants who Achieve ≥15% Body Weight Reduction
Time frame: Week 60
Proportion of Participants who Achieve ≥20% Body Weight Reduction
Time frame: Week 60
Change from Baseline in Waist Circumference
Time frame: Week 60
Change from Baseline in Systolic Blood Pressure
Time frame: Week 60
Percent Change from Baseline in Triglycerides
Time frame: Week 60
Percent Change from Baseline in non-high-density lipoprotein cholesteroal
Time frame: Week 60
Percent Change from Baseline in low-density lipoprotein cholesterol
Time frame: Week 60
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2023 (actual). Primary completion is estimated for Jun 2025, 18 months after the start.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 18 months is below that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mazdutide
Innovent Biologics (Suzhou) Co. Ltd. →